LY03017
Pharmaceutical compound
From Wikipedia, the free encyclopedia
LY03017, also known as LPM-526000133, is a serotonin 5-HT2 receptor antagonist which is under development for the treatment of schizophrenia[1][3][2] and Alzheimer's psychosis.[4] It acts specifically as a dual serotonin 5-HT2A receptor inverse agonist and serotonin 5-HT2C receptor antagonist.[1][3][2] The drug is under development by Luye Pharma Group in China.[1][3] As of December 2025, it is in phase 1 clinical trials.[1][3][2] The chemical structure of LY03017 does not yet appear to have been disclosed.[1]
Other namesLY-03017; LPM-526000133; LPM526000133
| Clinical data | |
|---|---|
| Other names | LY-03017; LPM-526000133; LPM526000133 |
| Routes of administration | Oral[1][2] |
| Drug class | Serotonin 5-HT2 receptor antagonist; Serotonin 5-HT2A receptor inverse agonist; Serotonin 5-HT2C receptor antagonist |
